• Home
  • About Atom
    • Management Team
    • Advisory Board
    • Investors
  • Our Programs
    • Pipeline
    • Gout & Hyperuricemia
    • Acute Gout
  • News & Events
  • Contact Us

Post navigation

Previous PostEndpoints: Atom Bioscience raises $83M in Series D for URAT1 inhibitor in chronic gout treatment
Next PostPipeline Review: Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout

Follow us on

  • Home
  • About Atom
  • Our Programs
  • News & Events
  • Contact Us

©2024 Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.